Condensed Statements of Cash Flows (Unaudited) (USD $)	9 Months Ended
	Sep. 30, 2011	Sep. 30, 2010
Cash flows from operating activities:
Net Loss	$ (1,077,049)	$ (319,244)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation expense	16,265	39,813
Amortization of patents	64,459	62,228
Amortization of debt discount	3,764	2,097
Common stock and options issued for compensation, consulting and vendor services	705,497	433,943
Loss on Earnings on Joint Venture	60,027
Bad debt expense (decrease) increase	(84,000)	5,000
Changes in operating assets and liabilities:
Increase in accounts receivable	(58,920)	(1,063,386)
Decrease (Increase) in inventories	253,036	(348,287)
Increase to advances to contract manufacturer	(890,735)	(1,730,791)
Decrease to prepaid expenses and other current assets	56,115	66,903
Decrease in other assets	19,433	59,257
Increase in accounts payable	257,771	1,900,035
Decrease in accrued expenses	372,603	167,734
Net cash used in operating activities	(301,735)	(724,698)
Cash flows from investing activities:
Purchases of property and equipment	(6,265)	(29,355)
Payment for patents rights	(27,414)	(69,350)
Net cash used in investing activities	(33,679)	(98,705)
Cash flows from financing activities:
Proceeds from exercise of stock options	25,000
Proceeds on sale of option rights	24,000
Proceeds from the sale of common stock	30,000
Net cash provided by financing activities	79,000
NET DECREASE IN CASH AND CASH EQUIVALENTS	(256,413)	(823,403)
Cash and cash equivalents at beginning of period	627,082	1,029,129
Cash and cash equivalents at end of period	370,669	205,726
Supplemental disclosure of cash flow information:
Interest paid	23,000	69,000
Invest in Joint Venture (contribution of patent rights)	$ 194,765